Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Hippocratic AI acquired Grove AI in January 2026 after the startup spent two years building voice agents for clinical trial recruitment. Grove’s technology speaks with patients, collects screening information and helps match them with enrolling studies. The deal shows how
A recent survey by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London shows that trust issues and regulatory uncertainty continue to slow artificial intelligence adoption in clinical trials. Although AI already delivers early value in clinical